[{"orgOrder":0,"company":"Laxxon Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"LXM.2","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Laxxon Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Laxxon Medical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Laxxon Medical \/ Not Applicable"},{"orgOrder":0,"company":"Laxxon Medical","sponsor":"Adare Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Laxxon Medical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Laxxon Medical \/ Laxxon Medical","highestDevelopmentStatusID":"2","companyTruncated":"Laxxon Medical \/ Laxxon Medical"},{"orgOrder":0,"company":"Laxxon Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"LXM.2","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Laxxon Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Enteric Coated Tablet","sponsorNew":"Laxxon Medical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Laxxon Medical \/ Inapplicable"},{"orgOrder":0,"company":"Laxxon Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Etilevodopa","moa":"||D3 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Laxxon Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Laxxon Medical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Laxxon Medical \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Laxxon Medical

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          RNA Therapeutics
                          Not Confirmed
                          RNA Therapeutics
                          Not Confirmed

                          Details : A new generation levodopa/carbidopa asset LXM.5 is being developed for the treatment of patients with parkinson's disease (PD).

                          Product Name : LXM.5

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 04, 2025

                          Lead Product(s) : Etilevodopa,Carbidopa

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          RNA Therapeutics
                          Not Confirmed
                          RNA Therapeutics
                          Not Confirmed

                          Details : LXM.2 is an once-daily oral, first-in-class GLP-1 agonist, currently being investigated for diabetes, metabolic syndrome and weight loss.

                          Product Name : LXM.2

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 15, 2025

                          Lead Product(s) : LXM.2

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          RNA Therapeutics
                          Not Confirmed
                          RNA Therapeutics
                          Not Confirmed

                          Details : The partnership aims to leverage Adare's state-of-the-art cGMP facilities and Laxxon's innovative 3D printing technology to bring innovative new oral dosage forms to market.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          September 18, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery

                          Recipient : Adare Pharma Solutions

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          04

                          BIO CEO & Investor
                          Not Confirmed
                          BIO CEO & Investor
                          Not Confirmed

                          Details : LXM.2 is a 3D printed oral glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of adults and pediatric patients 12 years and older with obesity.

                          Product Name : LXM.2

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 22, 2024

                          Lead Product(s) : LXM.2

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank